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pAfter  the  Second  World  War,  the  so-called  pharmacological
explosion  took  place,  leading  to  major  advances  in  the  treat-
ment  of  diseases  that  were  once  inevitably  fatal  or  disabling.
This  pharmacological  expansion  contributed  to  the  occur-
rence  of  catastrophic  incidents,  such  as  the  phocomelia
epidemic  attributed  to  thalidomide.  Since  then,  concerns
about  drug  safety  have  contributed  to  the  development  and
application  of  clinical  and  epidemiological  methods  to  assess
the  beneﬁts  and  potential  risks  of  any  type  of  therapeutic
intervention,  whether  pharmacological  or  not.1
Indisputably,  the  administration  of  a  medication  aims  to
obtain  a  beneﬁcial  effect  for  those  who  take  it.  Nonetheless,
it  is  important  that  the  assumptions  arising  from  the  analysis
of  scientiﬁc  evidence  are  not  forgotten:  ﬁrstly,  some  drugs
do  not  have  the  desired  efﬁcacy,  and  secondly,  regardless
of  their  beneﬁcial  effects,  every  medication  may  produce
undesired  effects.
When  a  drug  is  launched  on  the  market,  all  the  knowledge
about  it  is  based  on  pre-marketing  studies:  during  the  devel-
opment  of  the  molecule,  experimental  studies  on  its  effects
and  toxicity  are  conducted  in  animals  (pre-clinical  studies).
If  no  unacceptable  toxic  effects  are  observed,  the  ﬁrst  clini-
cal  trials  in  humans  are  conducted.  These  are  termed  phase
I,  II,  and  III  studies,  which  investigate  aspects  of  the  phar-
macokinetics,  toxicity,  and  efﬁcacy  in  humans.In  clinical  trials,  several  factors  may  interfere  with
the  results,  such  as  inclusion  and  exclusion  criteria,  sam-
ple  sizes,  and  even  ‘‘apparently  ethical’’  criteria,  which,
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license (https://creativecommons.org/licenses/by/4.0/).hile  fully  justiﬁed  in  the  early  stages  of  the  assessment
f  a  new  drug,  preclude  scientiﬁc  study  in  certain  popu-
ations.  For  a long  time,  with  some  exceptions,  children
ave  been  excluded  from  clinical  trials.  Only  in  phase  IV
post-marketing)  are  the  drugs  used  in  children,  which  may
ead  them  to  become  the  subjects  of  uncontrolled  clinical
ractice.1,2
This  practice  of  pediatric  prescription  without  clini-
al  evidence,  in  situations  that  are  different  from  those
tudied  and  advocated  (indications,  dosages,  extemporane-
us  formulations,  age  group  in  which  tested),  is  known  as
ff-label  use,  which  has  been  demonstrated  to  be  associ-
ted  with  an  increase  in  adverse  effects3--5 and  should  be
iscouraged.
In  this  issue  of  the  Revista  Paulista  de  Pediatria,
onc¸alves  and  Heineck  conducted  a  cross-sectional  study,
ith  a  simple  methodology.6 In  their  study,  the  authors
emonstrated  that,  of  the  total,  232  (31.7%)  prescriptions
ere  off-label,  and  the  following  types  and  frequency  were
bserved:  off-label  dose  --  90  (38.8%);  age  --  73  (31.5%);  and
dministration  frequency  --  68  (29.3%).  The  greatest  concern
as  the  ﬁnding  of  overdose  of  medications  whose  use  in  this
ituation  may  be  fatal,  such  as  salbutamol.
In  Brazil,  off-label  prescription  in  pediatrics  is  a  frequent
ractice.  Is  this  practice  necessary?  What  can  be  done  to
nsure  the  safety  of  children?
In  order  to  protect  the  health  of  children  and  to  ensure
hat  medications  are  used  in  a more  ethical  way,  in  2007
he  European  Union  issued  legislation  for  the  development
nd  authorization  of  pediatric  drugs.7 Since  then,  pharma-
eutical  companies  have  been  required  to  develop  their
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edicines  both  for  the  adult  and  pediatric  populations,  aim-
ng  to  adapt  the  drug  to  the  needs,  dosage,  dosage  form,
nd  administration  route,  among  others,  in  order  to  ensure
ffectiveness  and  that  safety  is  not  affected  by  the  risk  of
verdose.  A  Pediatric  Committee  was  also  created  to  eval-
ate  the  pediatric  investigation  plans  (PIPs)  presented  by
harmaceutical  companies.  The  committee  consists  of  12
epresentatives  of  the  member  states;  among  its  functions,
he  elaboration  of  an  inventory  of  speciﬁc  pediatric  needs
s  noteworthy.7
Also  in  2007,  the  World  Health  Organization  (WHO)  pub-
ished  the  ﬁrst  list  of  Essential  Medicines  for  Children,
hich  is  reviewed  every  2  years,  and  launched  the  ‘‘make
edicines  child  size’’  campaign,  in  order  to  raise  aware-
ess  and  promote  a  global  action  on  the  problem  of  lack  of
ediatric  formulations.8
In  2012,  under  the  Investigational  New  Drug  (IND)
rogram,  the  Food  and  Drug  Administration  (FDA),  the  reg-
lation  agency  of  the  United  States,  created  the  Safety  and
nnovation  Act  (FDASIA-2012),  which  established  the  Pedi-
tric  Study  Plan.  This  plan  is  required  for  new  molecules,
ew  indications,  new  dosage  forms,  new  dosages,  and  new
dministration  routes.9,10
In  Brazil,  there  are  isolated  initiatives  by  healthcare
nstitutions  that,  by  standardizing  drugs  and  creating  phar-
acology  committees,  among  other  measures,  are  able  to
valuate  the  off-label  use  of  drugs.  In  the  state  of  São
aulo,  the  Health  Surveillance  Center  (Centro  de  Vigilância
anitária  [CVS])  acts  in  the  pharmacovigilance  area  based
n  the  reports  of  adverse  events,  publishing  Therapeutic
lerts  on  Pharmacovigilance  in  the  Ofﬁcial  Journal.  The  CVS
as  recently  published  two  alerts,  ‘‘Methylphenidate:  indi-
ations  and  adverse  reactions’’  (July  2013)  and  ‘‘Risk  of
ancreatic  cancer  associated  with  incretin-based  therapy’’
February  2014).  Both  are  focused  on  alerting,  following
dverse  reactions  from  the  off-label  use  of  drugs.  The  ﬁrst
s  widely  used  in  children.11,12 At  the  federal  level,  the  Col-
egiate  Board  Resolution  (Resoluc¸ão  da  Diretoria  Colegiada
RDC])  No.  9,  of  20  February  2015,  which  aims  to  estab-
ish  the  procedures  and  requirements  for  the  conduction
f  clinical  drug  trials,  indicated  that  post-marketing  clin-
cal  trials  are  subject  only  to  the  Notiﬁcation  of  Clinical
rial.13
Above  all,  to  foster  ethical  off-label  drug  use,  it  is  nec-
ssary  that  this  exceptional  use  is  clinically  justiﬁed,  even
f  it  is  accompanied  by  clariﬁcation  and  consent  of  the  par-
nts  or  guardians.14 This  measure  can  be  taken  by  healthcare
acilities.  The  Brazilian  National  Health  Surveillance  Agency
Agência  Nacional  de  Vigilância  Sanitária  [Anvisa]),  follow-
ng  the  example  of  the  regulatory  body  of  the  European
nion,  should  establish  criteria  and  standards  that  stimu-
ate  comparative  studies  and  demonstrate  the  efﬁcacy  and
afety  of  medication  use  in  children.  When  promising,  ther-
pies  should  be  tested  in  controlled  clinical  trials  and  their
ackage  inserts  should  be  reformulated.unding
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